Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
6,151 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05839275 | The Combination of Radiotherapy,Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma(IRIS) | recruiting | Phase 1 / Phase 2 | 52 | Fudan UniversityOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT06000917 | A Study of Neoadjuvant TCHpy(Pyrotinib ,Trastuzumab,Carboplatin and Paclitaxel)for ER+/HER2+ Breast Cancer | recruiting | Phase 2 | 62 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER |
| 1 |
| Aug 21, 2023 |
| clinicaltrials |
| NCT06001151 | Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative(ACHELOUS) | recruiting | Phase 2 | 49 | Qian ChuOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05994170 | Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma(CTVp1-NPC) | recruiting | N/A | 454 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05994365 | Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma | recruiting | — | 380 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05933967 | A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 31 | Shandong Cancer Hospital and InstituteOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05991856 | Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for Aldosterone-producing Adenoma | recruiting | — | 45 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05985798 | Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC | recruiting | Phase 3 | 258 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05983107 | Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer | recruiting | Phase 2 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05983783 | Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05984342 | Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma | recruiting | Phase 1 | 50 | Affiliated Cancer Hospital of Shantou University Medical CollegeOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05984485 | The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer(TaLaR-02) | recruiting | Phase 3 | 766 | Sun Yat-sen UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT04416165 | Comparison of FDG and FAPI in Patients With Various Types of Cancer | recruiting | N/A | 3,000 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05914389 | Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer(ICONIC) | recruiting | Phase 2 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05980715 | PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy(HNC-SYSU-003) | recruiting | Phase 3 | 324 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05981001 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 170 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05981014 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 196 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05623267 | Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT(SURPASS) | recruiting | Phase 2 / Phase 3 | 346 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05976412 | Regional Lymph Node Irradiation for High-risk pN0 Breast Cancer | recruiting | N/A | 1,355 | Ruijin HospitalOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05869474 | Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma | recruiting | N/A | 206 | Changhai HospitalOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05965115 | The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study(CHAPERONE) | recruiting | — | 10,000 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05967949 | A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. | recruiting | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05970198 | Helical Tomotherapy in Multiple Myeloma | recruiting | N/A | 58 | Fuling ZhouOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05838053 | Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | recruiting | — | 446 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05830500 | Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma | recruiting | Phase 4 | 360 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 25, 2023 | clinicaltrials |
| NCT03786003 | ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007) | recruiting | N/A | 1,086 | Fudan UniversityOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05956639 | Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC | recruiting | Phase 3 | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05709769 | Radiomics-based Malnutrition for Cervical Cancer. | recruiting | — | 150 | Zhejiang Provincial People's HospitalOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05954897 | Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 29 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05846750 | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma | recruiting | Phase 2 | 59 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05952661 | Minimally Residual of Esophageal Cancer 001(ECMRD-001) | recruiting | — | 56 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05950087 | Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy | recruiting | — | 30 | Guizhou Provincial People's HospitalOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT05837052 | A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC | recruiting | Phase 2 | 49 | Zhejiang UniversityOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05862168 | Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma :A Single-arm, Prospective, Phase II Trial | recruiting | Phase 2 | 30 | Weijia Fang, MDOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05947487 | CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05948033 | CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05945407 | Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer | recruiting | N/A | 57 | Peking University People's HospitalOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05430399 | Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer | recruiting | Phase 3 | 349 | Sun Yat-sen UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05443841 | Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)(ECTOP-2005) | recruiting | — | 385 | Fudan UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05943379 | RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects | recruiting | Phase 2 | 85 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05941338 | Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC(HNC-SYSU-001) | recruiting | Phase 2 | 100 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05940441 | A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma | recruiting | — | 74 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05940532 | A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC | recruiting | Phase 2 | 41 | Hunan Cancer HospitalOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05938309 | A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors | recruiting | — | 194 | Fujian Medical UniversityOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT05931263 | A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL | recruiting | Phase 3 | 104 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05931328 | The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients. | recruiting | Phase 2 | 28 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05926726 | GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | recruiting | N/A | 12 | RenJi HospitalOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05913089 | A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer | recruiting | Phase 2 | 58 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05883852 | EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer | recruiting | Phase 3 | 1,406 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05917431 | Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC | recruiting | Phase 2 | 39 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 23, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials